Pleiotropic Effects of Ticagrelor: Influence on Gene and Protein Expression in HUVEC and HepG2, and Bacterial Survival

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 Aug 12

PMID 35959420

Authors

Ugne Meskauskaite

Silvija Andruskeviciute

Ieva ciapiene

Agne Giedraitiene

Vaiva Lesauskaite

Vacis Tatarunas

Affiliations

Soon will be listed here.

Abstract

Background: Antiplatelet drugs, such as ticagrelor, which target platelet P2Y receptors, are used for prevention of ischemic heart disease. Ticagrelor is also known to have pleiotropic effects of unknown mechanisms. Ticagrelor could influence the expression of molecules involved in resolution of inflammation. This study aimed to investigate if ticagrelor could change the expression of and its encoded protein concentration and, additionally, to determine ticagrelor possible antibacterial activity against gram-negative bacteria.

Methods: expression was determined in HUVEC and HepG2 cell lines by qPCR. CYP4F2 protein concentration was determined by ELISA. Antibiotic susceptibility testing was performed using a disc diffusion method.

Results: Ticagrelor was observed to reduce the expression of in HUVEC and HepG2 cell lines. It also reduced CYP4F2 protein levels in HUVEC cells. Ticagrelor had no bactericidal activity against gram-negative third generation cephalosporin resistant .

Conclusion: Ticagrelor reduced CYP4F2 protein concentration in HUVEC, and expression in HUVEC and HepG2 cells, but had no effect on third-generation cephalosporin-resistant strains.

Citing Articles

The Effect of Platelet Activity, Genetic Polymorphism, and Renal Function on the Development of Ticagrelor-Related Dyspnea in Patients with Acute Coronary Syndrome.

Tamakauskas V, Zaliunas R, Lesauskaite V, Kupstyte-Kristapone N, ciapiene I, Sakalyte G Drug Des Devel Ther. 2024; 18:109-119.

PMID: 38287944 PMC: 10822766. DOI: 10.2147/DDDT.S435477.

References

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

Halim H, Pinkaew D, Chunhacha P, Sinthujaroen P, Thiagarajan P, Fujise K . Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS One. 2019; 14(6):e0218934. PMC: 6594647. DOI: 10.1371/journal.pone.0218934. View

Hoopes S, Garcia V, Edin M, Schwartzman M, Zeldin D . Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 2015; 120:9-16. PMC: 4575602. DOI: 10.1016/j.prostaglandins.2015.03.002. View

Jeong H, Hong S, Cho S, Kim J, Cho J, Lee S . Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective,.... JACC Cardiovasc Interv. 2017; 10(16):1646-1658. DOI: 10.1016/j.jcin.2017.05.064. View

Valgimigli M, Mehran R, Franzone A, da Costa B, Baber U, Piccolo R . Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv. 2021; 14(4):444-456. DOI: 10.1016/j.jcin.2020.11.046. View

Christmas P . Role of Cytochrome P450s in Inflammation. Adv Pharmacol. 2015; 74:163-92. DOI: 10.1016/bs.apha.2015.03.005. View

Reiner M, Akhmedov A, Stivala S, Keller S, Gaul D, Bonetti N . Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. Cardiovasc Res. 2016; 113(1):61-69. DOI: 10.1093/cvr/cvw233. View

Lancellotti P, Musumeci L, Jacques N, Servais L, Goffin E, Pirotte B . Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria. JAMA Cardiol. 2019; 4(6):596-599. PMC: 6506905. DOI: 10.1001/jamacardio.2019.1189. View

Fan F, Ge Y, Lv W, Elliott M, Muroya Y, Hirata T . Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Front Biosci (Landmark Ed). 2016; 21(7):1427-63. PMC: 5064940. DOI: 10.2741/4465. View

10.

Aquila G, Vieceli Dalla Sega F, Marracino L, Pavasini R, Cardelli L, Piredda A . Ticagrelor Increases and mRNA Levels in Peripheral Blood Cells from Patients with Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease. Int J Mol Sci. 2020; 21(5). PMC: 7084534. DOI: 10.3390/ijms21051576. View

11.

Alemayehu M, Kim R, Lavi R, Gong I, DAlfonso S, Mansell S . Effect of Ticagrelor Versus Clopidogrel on Vascular Reactivity. J Am Coll Cardiol. 2017; 69(17):2246-2248. DOI: 10.1016/j.jacc.2017.02.048. View

12.

Kubisa M, Jezewski M, Gasecka A, Siller-Matula J, Postula M . Ticagrelor - toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018; 14:129-140. PMC: 5775739. DOI: 10.2147/TCRM.S152369. View

13.

Roman R, Fan F . 20-HETE: Hypertension and Beyond. Hypertension. 2018; 72(1):12-18. PMC: 6002933. DOI: 10.1161/HYPERTENSIONAHA.118.10269. View

14.

Ganbaatar B, Fukuda D, Salim H, Nishimoto S, Tanaka K, Higashikuni Y . Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis. 2018; 275:124-132. DOI: 10.1016/j.atherosclerosis.2018.05.053. View

15.

Vieceli Dalla Sega F, Fortini F, Aquila G, Pavasini R, Biscaglia S, Bernucci D . Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF). Front Physiol. 2018; 9:337. PMC: 5900783. DOI: 10.3389/fphys.2018.00337. View

16.

Adamski P, Kozinski M, Ostrowska M, Fabiszak T, Navarese E, Paciorek P . Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thromb Haemost. 2014; 112(2):224-42. DOI: 10.1160/TH13-11-0915. View

17.

Westphal C, Konkel A, Schunck W . Cytochrome p450 enzymes in the bioactivation of polyunsaturated Fatty acids and their role in cardiovascular disease. Adv Exp Med Biol. 2015; 851:151-87. DOI: 10.1007/978-3-319-16009-2_6. View

18.

Waldman M, Peterson S, Arad M, Hochhauser E . The role of 20-HETE in cardiovascular diseases and its risk factors. Prostaglandins Other Lipid Mediat. 2016; 125:108-17. DOI: 10.1016/j.prostaglandins.2016.05.007. View

19.

Turpie A, Esmon C . Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation. Thromb Haemost. 2011; 105(4):586-96. DOI: 10.1160/TH10-10-0683. View

20.

Chen L, Joseph G, Zhang F, Nguyen H, Jiang H, Gotlinger K . 20-HETE contributes to ischemia-induced angiogenesis. Vascul Pharmacol. 2016; 83:57-65. PMC: 4939128. DOI: 10.1016/j.vph.2016.04.002. View